Florida Poly assistant professor receives Fulbright to continue research in Canada
Kelley, an assistant professor of mechanical engineering, will travel to Canada in August to collaborate on academic curriculum development at the University of Windsor in Ontario, Florida Poly said in a news release. Kelley's research focuses on Parkinson's disease diagnosis and wearable care technology.
The Fulbright Specialist Program provides an opportunity for U.S. academics and established professionals to engage in project-based exchanges at host institutions around the world, the release said.
During Kelley's project at UWindsor, he will primarily collaborate with Jalal Ahamed, associate professor at UWindsor's Department of Mechanical, Automotive and Materials Engineering, in building mechatronics systems curriculum while incorporating biomedical aspects, the release said.
Mechatronics is an interdisciplinary field that combines mechanical engineering, electronics and computer systems to design and build intelligent, automated devices and processes, the release said.
'This is a really great opportunity, and I'm excited to be a part of it,' Kelley said in the release. 'Project-based learning engages students and helps them become better problem solvers because instead of doing everything on paper, they're physically working on something and accomplishing a goal.'
Kelley collaborated last year with Ahamed to develop sensors that capture changes in the gait of a person with Parkinson's disease. Ahamed was at Florida Poly as a Fulbright Canada research chair, the release said.
Kelley will conduct seminars, workshops and lectures on project-based and experiential learning. Upon his return, Kelley plans to begin implementing the new methods into Florida Poly's mechatronic systems, human robotics and other courses, the release said.
'Dr. Kelley's selection as a Fulbright Specialist highlights Florida Poly's growing role on the global stage,' said Mustapha Achoubane, the senior adviser for international relationships at Florida Poly. 'We are dedicated to fostering international partnerships and academic excellence that empower our faculty and students to become leaders and innovators in science and technology worldwide.'
This article originally appeared on The Ledger: Florida Poly assistant professor is named Fulbright Specialist
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
21 hours ago
- New York Post
Trump can rein in healthcare costs AND win medical breakthroughs — here's how
Of all the problems bedeviling the American healthcare system, the high cost of pharmaceuticals is one of those most commonly cited by patients. Polling finds that most Americans think drugs are too expensive, and they're often right — even if pricey medications beat alternatives like surgery, hospitalization or living with pain. President Donald Trump has promised to implement healthcare reforms that both increase innovation and improve affordability. Advertisement Some see these as contradictory pursuits — but when it comes to pharmaceuticals, both of the president's goals can be achieved at the same time. This week the two of us, along with a team of top health and economic experts, launched Most Favored Patients, a working group aimed at developing reforms that will lower drug prices in ways that won't hinder or delay new drug development. Before we suggest policies that could work, let's be clear about what doesn't: government-mandated price controls. Advertisement Top-down edicts that remove the profit motive from drug research and development will do more harm than good, impeding the race to identify cures for cancer, Alzheimer's, Parkinson's, epilepsy and other cruel diseases. It's a short-sighted solution, too: It ignores the reality that 93% of US prescriptions are for very cheap generics — indeed, cheaper here than abroad — that emerge after innovators earn the necessary returns on their investments. Instead, let's try some innovations that make both medical and economic sense. First, do the easy stuff first and allow patients to buy medicines from pharmaceutical companies directly. Advertisement Our recent poll of 1,000 battleground-state voters found overwhelming 86% support for this concept, which would lower drug prices by avoiding expensive retail markups imposed by insurance companies and others. Most voters also favor Trump's intention to rein in costly middlemen like the highly concentrated pharmacy benefit manager industry, which negotiates drug prices for insurance companies. We also must require foreign countries to pay their fair share for medical innovations developed in the United States — that is, nearly all of them. Trump can use his NATO negotiations as a model here: Just as he has required Europe to pony up more for the benefits of NATO security through minimum levels of military spending, he could convince trading partners to spend more of their GDP on new drugs. Advertisement Right now, more than 70% of global pharmaceutical earnings come from the United States, even though we generate less than a quarter of global GDP. We annually spend $13,000 on healthcare per capita, while the rest of the developed world spends far less than $10,000 — partly because we allow more free-market healthcare pricing than other nations do. Trump is already implementing some of these reforms in his America First trade deals, securing some $300 billion worth of foreign commitments for new domestic pharmaceutical R&D, manufacturing and workforce investments. These commitments share the burden of finding cures that will benefit all of humanity — while fueling the American research engine that justifies the investments. Next, the Food and Drug Administration must thoroughly overhaul its antique, snail's-pace drug approval process: Many potential wonder drugs developed by small biomedical firms are shelved when that process' exorbitant costs and delays drain their capital. The FDA should fast-track experimental drugs for crippling and lethal diseases, and should expedite 'Right To Try' rules to get promising drugs to the people who need them. In addition, we believe the FDA should loosen its regulations and use economic criteria, not just clinical ones, to determine whether a drug may be fast-tracked for approval: Put simply, cheaper drugs should be allowed to come to market faster. Advertisement Finally, we're confident that price transparency in drugs and all other medical services would help drive prices down and encourage more comparison-shopping by patients. We don't buy food or gas or homes without knowing their price — but that's too often the case with drugs, hospitals and medical procedures. Republicans have been missing out on the political benefits of seizing on common-sense reforms like these. Advertisement Voters consistently view the GOP as being less caring and less reliable on solving our nation's healthcare concerns. That's made them cower. They keep their mouths shut and flee from any discussion of voters' valid complaints — and often lose elections as a result. As the midterms approach, Republicans who promote innovation with our Most Favored Patient proposals will help bring down costs, ensure American biomedical innovative supremacy, and save lives. Advertisement Everyone is on board with that. Stephen Moore is a co-founder of Unleash Prosperity, where Tomas Philipson is a senior research fellow.
UPI
2 days ago
- UPI
Myanmar's junta-picked acting president dies
Aug. 7 (UPI) -- Myanmar's junta-appointed acting President U Myint Swe died Thursday morning, weeks after he was declared unable to perform his mostly ceremonial duties due to Parkinson's disease. He was 74. Myint Swe died at 8:28 a.m. local time at the No. 2 Defense Services General Hospital, the National Defense Security Council said in a statement. Myint Swe, a former general, was vice president of Myanmar during the Feb. 1, 2021, military coup. He was appointed acting president after the country's civilian leader, Daw Aung San Suu Kyi, was arrested. According to the National Defense and Security Council, Myint Swe began experiencing "sluggishness in movement and the ability to consume food and nutrients" in early 2023, and was soon diagnosed with Parkinson's, which the U.S. Centers for Disease Control and Prevention calls is a progressive nervous system disorder that afects movement and has no cure. In April of last year, he received medical treatment at Singapore's Mount Elizabeth Medical Center. Then from late May to mid-June of this year, he received treatment again, this time at the No. 2 Defense Services General Hospital in Myanmar. According to officials, Myint Swe experience wight loss, loss of appetite, fever and a decline in cognitive function last month, and was placed on medical leave July 18 and then hospitalized on July 24. He was listed as in critical condition after being hospitalized in the Special Intensive Care Unit of the No. 2 Defense Services General Hospital, where he died Thursday morning. A period of mourning has been declared from Thursday to Monday, during which the national flag will be flown at half-mast. The coup of 2021 has upended the country, which has been embroiled in civil war since. According to the Assistance Association for Political Prisoners, more than 7,000 civilians have been killed by junta forces amid the civil war and 22,000 remain arbitrarily detained. The United Nations estimates 22 million are in need of assistance and more than 3.5 million have been displaced by the fighting.
Fox News
3 days ago
- Fox News
Florida Poly and OCOM offer accelerated medical degree to address physician shortage
Amid a growing healthcare provider shortage in Polk County, Florida Polytechnic University and the Orlando College of Osteopathic Medicine have announced a new six-year accelerated medical degree program designed to fast-track the next generation of doctors. In Polk County, reports show that they have half as many doctors, dentists and pediatricians per 100,000 residents than the state average. This shortage has been linked to a rapid growth in the population. They also report a notable increase in emergency room visits linked to non-emergent care and general chronic disease management due to the absence of primary care access. With the new initiative, students will be able to complete both a Bachelor of Science and Doctor of Osteopathic Medicine degree in just six years — compared to the traditional eight years (four for undergrad, four for medical school), not including residency. The accelerated curriculum will assist students in getting both degrees needed by addressing physician shortages while making medical education accessible. The program will also promote STEM-medicine integration, cost-effective education, and innovative academic partnerships. Dr. Kiran C. Patel, OCOM's Founder, and Dr. Devin Stephenson, Florida Poly's President, announced that they had signed an agreement to move forward with the endeavor in July of this year. The program will limit acceptance to 20 high-achieving students a year and will require a minimum SAT score of 1390, an ACT score of 31, and a GPA of 3.5. However, a Medical College Admission Test (MCAT) will not be required. "This is a transformative opportunity for students who want to become physicians and are eager to begin serving their communities," Stephenson said. "By combining rigorous STEM education with a clear, accelerated track to medical school, we are reimagining what's possible in health education and responding to a critical need for more doctors across Florida and beyond. This agreement also reflects Florida Poly's 25|30 Strategic Plan's commitment to build capacity through enhanced partnership development, strengthening our role as a driver of innovation and impact." The hopes of the new program are that, by limiting entry to high-achieving students and eliminating the MCAT requirement, the program will be able to produce local physicians faster, more affordably, and in greater alignment with Florida's rapidly growing healthcare needs.
